IMGN853 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: mirvetuximab soravtansine

Filter by location:

New Haven, Connecticut1 trial

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Smilow Cancer Hospital at Yale New Haven

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.